Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EDSA
Upturn stock ratingUpturn stock rating

Edesa Biotech Inc (EDSA)

Upturn stock ratingUpturn stock rating
$2.01
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/17/2025: EDSA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $13

Year Target Price $13

Analyst’s Price TargetsFor last 52 week
$13Target price
Low$1.55
Current$2.01
high$5.59

Analysis of Past Performance

Type Stock
Historic Profit -38.74%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/17/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.40M USD
Price to earnings Ratio -
1Y Target Price 10.33
Price to earnings Ratio -
1Y Target Price 10.33
Volume (30-day avg) -
Beta 0.38
52 Weeks Range 1.55 - 5.59
Updated Date 06/30/2025
52 Weeks Range 1.55 - 5.59
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.55

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -35.29%
Return on Equity (TTM) -58.78%

Valuation

Trailing PE -
Forward PE 0.17
Enterprise Value 13379036
Price to Sales(TTM) 120477.93
Enterprise Value 13379036
Price to Sales(TTM) 120477.93
Enterprise Value to Revenue 128525.38
Enterprise Value to EBITDA -1.25
Shares Outstanding 7022680
Shares Floating 3728761
Shares Outstanding 7022680
Shares Floating 3728761
Percent Insiders 28.41
Percent Institutions 43.53

Analyst Ratings

Rating 5
Target Price 13
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Edesa Biotech Inc

stock logo

Company Overview

overview logo History and Background

Edesa Biotech Inc. is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing innovative treatments for inflammatory and immune-related diseases with unmet medical needs. Founded in 2007, Edesa's initial focus was on dermatology, expanding later to include other areas. Key milestones include clinical trial advancements of their lead product candidates.

business area logo Core Business Areas

  • Pharmaceutical Development: Edesa develops and tests pharmaceutical products through clinical trials, seeking regulatory approval and eventual commercialization. Their focus is on dermatological and other immune-related conditions.

leadership logo Leadership and Structure

Dr. Par Nijhawan is the Chief Executive Officer. The company has a board of directors overseeing the strategic direction. Edesa operates with a relatively small team, outsourcing certain functions like manufacturing and clinical trial management.

Top Products and Market Share

overview logo Key Offerings

  • EB05 (Phase 3 stage asset, anti-inflammatory sNDA candidate): EB05 is Edesa's main product candidate, an anti-inflammatory sNDA candidate currently in Phase 3 trials for moderate-to-severe chronic allergic contact dermatitis (ACD). Market share is currently 0% as it's not yet approved. Competitors include topical corticosteroids and calcineurin inhibitors like tacrolimus and pimecrolimus. This product revenue cannot be reported as it has not been approved yet.
  • EB01 (Topical treatment): EB01 is an investigational product for the treatment of atopic dermatitis. There is no revenue from this product. Competitors include topical corticosteroids, calcineurin inhibitors and monoclonal antibodies.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and research-intensive. Key trends include personalized medicine, rising healthcare costs, and stringent regulatory requirements. Companies need strong pipelines and funding to succeed.

Positioning

Edesa is a small player focusing on niche markets within dermatology and other immune-related diseases. Its competitive advantage relies on developing novel therapies for unmet needs. They are focused on an anti-inflammatory medication for ACD.

Total Addressable Market (TAM)

The global atopic dermatitis market is expected to be worth around $18 billion. Edesa, with its investigational product EB01, is positioned to try to compete for a piece of this market. The allergic contact dermatitis (ACD) market TAM is harder to quantify as a standalone, but it is a significant part of the overall dermatology market, potentially worth billions.

Upturn SWOT Analysis

Strengths

  • Focus on unmet medical needs
  • Experienced management team
  • Promising clinical trial results
  • Partnerships with research institutions

Weaknesses

  • Limited financial resources
  • Reliance on a few key products
  • High risk of clinical trial failure
  • Small market capitalization

Opportunities

  • Potential for breakthrough therapies
  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Government grants and funding

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles and delays
  • Patent expiration
  • Economic downturn impacting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • VRX
  • LEO
  • BMY

Competitive Landscape

Edesa faces significant competition from larger, more established pharmaceutical companies. Edesa's advantage lies in developing novel therapies for niche markets.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited as Edesa is a development-stage company. Growth is expected to occur if products are approved and commercialized.

Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of its product candidates. Analyst projections are speculative and subject to change.

Recent Initiatives: Recent initiatives include advancing EB05 through Phase 3 clinical trials and seeking partnerships for further development and commercialization.

Summary

Edesa Biotech is a clinical-stage company focused on dermatology and immunology. The company has potential with its lead product EB05 progressing through trials. However, it faces substantial risks with limited resources and a dependence on positive clinical trial outcomes. Strong competition and regulatory hurdles add further challenges, requiring careful risk management.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The data provided may not be exhaustive, and actual results may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Edesa Biotech Inc

Exchange NASDAQ
Headquaters Markham, ON, Canada
IPO Launch date 2015-11-05
CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.